Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lucid Diagnostics Inc LUCD

Healthcare Medical Devices
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a... see more

Recent & Breaking News (NDAQ:LUCD)

Lucid Diagnostics to Participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference

Business Wire February 10, 2022

PAVmed and Lucid Diagnostics Welcome New Full-Time Investor Relations Team

Business Wire January 12, 2022

Lucid Diagnostics to Participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference

Business Wire January 6, 2022

PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth

Business Wire December 1, 2021

Lucid Diagnostics to Present at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

Business Wire November 17, 2021

PAVmed and Lucid Provide Business Update and Preliminary Third Quarter 2021 Financial Results

Business Wire November 16, 2021

PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers

Business Wire November 11, 2021

PAVmed and Lucid to Hold Joint Business Update Conference Call on November 16, 2021

Business Wire November 3, 2021

Lucid Diagnostics' EsoGuard Esophageal DNA Test Wins "Diagnostics Innovation of the Year" Award

Business Wire October 28, 2021

Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer

Business Wire October 21, 2021

Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering

GlobeNewswire October 18, 2021

Lucid Diagnostics Announces Pricing of Initial Public Offering

Business Wire October 13, 2021